1 / 5

Cardiac Biomarkers Market Is Expected To Reach $20,718.8 Million by 2030

In 2021, the global cardiac biomarkers market accounted for an $8,459.6 million value, which is set to reach a $20,718.8 million value by 2030, growing at a 10.5% CAGR from 2021 to 2030. This is owing to the increasing requirement for point-of-care testing kits, growing incidence of acute coronary syndrome (ACS), and demand for high specificity in the identification of cardiac disorders.

psmarketresearch2017
Download Presentation

Cardiac Biomarkers Market Is Expected To Reach $20,718.8 Million by 2030

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rising Prevalence of CVDs Leads to Increasing Demand for Cardiac Biomarkers 1 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

  2. In 2021, the cardiac biomarkers industry contributes $8,459.6 million, and it is projected to rise at a rate of 10.5%, to capture $20,718.8 million revenue in 2030. It is led by the rising prevalence of acute coronary syndrome, increasing point-of-care testing kit demand, and technological advancements in the industry. Moreover, the surging investments in biomarker research, increasing CVDs incidences, and rising geriatric population are projected to boost the industry growth. Troponin holds a significant share of the industry, accounting for 35%, and it is projected to experience significant growth in the coming years. It is due to extraordinary specifications, and protein complex capacity to help in diagnosing cardiac problems, such as ACS, precisely. In addition, the growing incidences of myocardial infarction proliferate the industry led by the wide usage of the troponin to diagnose this condition. Moreover, myocardial creatine kinase is projected to experience the next- significant growth after troponin, in the coming future. To receive free sample pages of this report: https://www.psmarketresearch.com/market-analysis/cardiac- biomarker-market/report-sample Moreover, the cardiac test kits offer a variety of combined tests for identifying the presence of biomarkers, providing ease in cardiac disorders identification. In addition, the rising demand for these kits is led by fast diagnosis facilitated by them and thus enabling early treatment.Furthermore, they offer chest discomfort diagnosis with the easy identification of risk factors before it turns out to be a major cardiac event. Around 18 million deaths worldwide are caused by cardiac vascular diseases each year, which accounts for 31% of all fatalities. Therefore, companies are focusing to offer test kits to facilitate the biomarkers detection for a better understanding of CVDs pathogenesis. Some of the major biomarkers are C- reactive protein (CRP), lipoprotein-associated phospholipase A2, N-terminal prohormone BNP, and cystatin C. Moreover, the surging use of biomarkers in ACS diagnosis and risk assessment proliferates the industry growth. In addition, laboratory testing captures a substantial share of the industry, accounting for 60%, and it is projected to retain its position in the near future. It is led by increasing healthcare expenditure, reforms for improving the healthcare infrastructure, surging disposable incomes as well as initiatives of private and government sectors for the prevention of heart diseases. 2 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

  3. Moreover, point-of-care testing is projected to experience substantial growth in the near future, led by its increased adoption by healthcare professionals for patient monitoring, in cases of chest pain in critical care centers. Inquire before purchase: https://www.psmarketresearch.com/send- enquiry?enquiry-url=cardiac-biomarker-market In addition, myocardial infarction contributes significant revenue, accounting for $3.0 billion, and it is projected to retain its position in the near future. It is attributed to its rising prevalence due to lifestyle changes, including unhealthy food consumption, and excessive smoking, along with coronary artery disease. Moreover, the growing demand for biomarker tests for early diagnosis of conditions that may cause a major cardiac event leads to cardiac biomarkers industry propulsion. Furthermore, North America captures the largest share of the cardiac biomarkers industry, accounting for 35%. It is ascribed to the extensive precision medicine usage of the biomarkers, and growing adoption of biomarkers for cardiac disease diagnosis. Therefore, the rising prevalence of CVDs, with growing incidences of death caused by heart failures, leads to increasing demand for cardiac biomarkers for early diagnosis of the conditions. Market Size Breakdown by Segment Market Size Breakdown by Segment The study offers a comprehensive market segmentation analysis along with market estimation for the period 2017-2030. Based on Type Based on Type Troponins Myocardial Muscle Creatine Kinase Myoglobin BNPs IMA ALT/AST Based on Application Based on Application Myocardial Infarction Congestive Heart Failure Acute Coronary Syndrome Atherosclerosis Based on Testing Location Based on Testing Location • • • • • • • • • • 3 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

  4. Laboratory Testing Point-of-Care Testing Geographical Analysis Geographical Analysis North America • • • oU.S. oCanada Europe • oGermany oFrance oU.K. oItaly oSpain Asia-Pacific • oChina oIndia oJapan oSouth Korea oAustralia Latin America • oBrazil oMexico Middle East and Africa • oSaudi Arabia oSouth Africa 4 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

  5. Disclaimer: P&S Intelligence always keeps its customers’ interests at the core while carrying out research activities. P&S Intelligence ensures the reliability and accuracy of information and data provided in its market research publications. However, the information in publications is subject to fluctuations, as it is based on primary interviews of officials from various companies or organizations. P&S Intelligence is not responsible for any incorrect data provided by the key industry players of the concerned domain. The information or analysis in P&S Intelligence publications represents opinions based on research and should not be interpreted as statements of fact. Information in this report was believed to be correct at the time of publication, but cannot be guaranteed. P&S Intelligence does not endorse any product, service, or vendor depicted in its research publications. All intellectual properties, including trademarks and copyrights, belong to their respective owners and may be protected by copyright. Under no circumstance can these be reproduced in any form without prior written agreement of their owners. An order for market research report is intended for internal use of the company only and not for disclosure to third parties or any other publication in general. No service, report, or part thereof provided by P&S Intelligence can be reproduced, republished, resold, revealed, distributed, circulated, or sublicensed in any medium or form now realized or hereafter become realized, including but not limited to, all forms of optical-based media, magnetic, electronic, or digital, without a written permission from Prescient & Strategic Intelligence Pvt. Ltd. Kindly write to: enquiry@psmarketresearch.com B-13, Sector – 2, Noida, U.P. – 201301, INDIA Contact No: +91 120 4541 337 US/Canada Toll-Free: 1-888-778-7886 5 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

More Related